114 related articles for article (PubMed ID: 27493124)
1. Different interactomes for p70-S6K1 and p54-S6K2 revealed by proteomic analysis.
Pavan IC; Yokoo S; Granato DC; Meneguello L; Carnielli CM; Tavares MR; do Amaral CL; de Freitas LB; Paes Leme AF; Luchessi AD; Simabuco FM
Proteomics; 2016 Oct; 16(20):2650-2666. PubMed ID: 27493124
[TBL] [Abstract][Full Text] [Related]
2. The S6K protein family in health and disease.
Tavares MR; Pavan IC; Amaral CL; Meneguello L; Luchessi AD; Simabuco FM
Life Sci; 2015 Jun; 131():1-10. PubMed ID: 25818187
[TBL] [Abstract][Full Text] [Related]
3. Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR.
Rosner M; Hengstschläger M
Oncogene; 2011 Nov; 30(44):4509-22. PubMed ID: 21602892
[TBL] [Abstract][Full Text] [Related]
4. The polyproline-motif of S6K2: eIF5A translational dependence and importance for protein-protein interactions.
Meneguello L; Barbosa NM; Pereira KD; Proença ARG; Tamborlin L; Simabuco FM; Iwai LK; Zanelli CF; Valentini SR; Luchessi AD
J Cell Biochem; 2019 Apr; 120(4):6015-6025. PubMed ID: 30320934
[TBL] [Abstract][Full Text] [Related]
5. Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway.
Goh ET; Pardo OE; Michael N; Niewiarowski A; Totty N; Volkova D; Tsaneva IR; Seckl MJ; Gout I
J Biol Chem; 2010 May; 285(22):17065-76. PubMed ID: 20308064
[TBL] [Abstract][Full Text] [Related]
6. S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.
Amaral CL; Freitas LB; Tamura RE; Tavares MR; Pavan IC; Bajgelman MC; Simabuco FM
BMC Cancer; 2016 Aug; 16():602. PubMed ID: 27491285
[TBL] [Abstract][Full Text] [Related]
7. Identification of the general transcription factor Yin Yang 1 as a novel and specific binding partner for S6 kinase 2.
Ismail HM; Myronova O; Tsuchiya Y; Niewiarowski A; Tsaneva I; Gout I
Cell Signal; 2013 May; 25(5):1054-63. PubMed ID: 23403125
[TBL] [Abstract][Full Text] [Related]
8. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.
Bostner J; Karlsson E; Eding CB; Perez-Tenorio G; Franzén H; Konstantinell A; Fornander T; Nordenskjöld B; Stål O
Endocr Relat Cancer; 2015 Jun; 22(3):331-43. PubMed ID: 25972244
[TBL] [Abstract][Full Text] [Related]
9. Development of monoclonal antibodies specific to ribosomal protein S6 kinase 2.
Savinska L; Skorokhod O; Klipa O; Gout I; Filonenko V
Hybridoma (Larchmt); 2012 Aug; 31(4):289-94. PubMed ID: 22894784
[TBL] [Abstract][Full Text] [Related]
10. Modulation of hypothalamic S6K1 and S6K2 alters feeding behavior and systemic glucose metabolism.
Tavares MR; Lemes SF; de Fante T; Saenz de Miera C; Pavan ICB; Bezerra RMN; Prada PO; Torsoni MA; Elias CF; Simabuco FM
J Endocrinol; 2020 Jan; 244(1):71-82. PubMed ID: 31557728
[TBL] [Abstract][Full Text] [Related]
11. Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.
Sridharan S; Basu A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054043
[TBL] [Abstract][Full Text] [Related]
12. Unique and Redundant Functions of p70 Ribosomal S6 Kinase Isoforms Regulate Mesenchymal Cell Proliferation and Migration in Pulmonary Fibrosis.
Madala SK; Sontake V; Edukulla R; Davidson CR; Schmidt S; Hardie WD
Am J Respir Cell Mol Biol; 2016 Dec; 55(6):792-803. PubMed ID: 27438654
[TBL] [Abstract][Full Text] [Related]
13. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.
Karlsson E; Magić I; Bostner J; Dyrager C; Lysholm F; Hallbeck AL; Stål O; Lundström P
PLoS One; 2015; 10(12):e0145013. PubMed ID: 26698305
[TBL] [Abstract][Full Text] [Related]
14. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway.
Pende M; Um SH; Mieulet V; Sticker M; Goss VL; Mestan J; Mueller M; Fumagalli S; Kozma SC; Thomas G
Mol Cell Biol; 2004 Apr; 24(8):3112-24. PubMed ID: 15060135
[TBL] [Abstract][Full Text] [Related]
15. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
Pérez-Tenorio G; Karlsson E; Waltersson MA; Olsson B; Holmlund B; Nordenskjöld B; Fornander T; Skoog L; Stål O
Breast Cancer Res Treat; 2011 Aug; 128(3):713-23. PubMed ID: 20953835
[TBL] [Abstract][Full Text] [Related]
16. Histone acetyltransferases interact with and acetylate p70 ribosomal S6 kinases in vitro and in vivo.
Fenton TR; Gwalter J; Ericsson J; Gout IT
Int J Biochem Cell Biol; 2010 Feb; 42(2):359-66. PubMed ID: 19961954
[TBL] [Abstract][Full Text] [Related]
17. Characterization of S6K2, a novel kinase homologous to S6K1.
Lee-Fruman KK; Kuo CJ; Lippincott J; Terada N; Blenis J
Oncogene; 1999 Sep; 18(36):5108-14. PubMed ID: 10490847
[TBL] [Abstract][Full Text] [Related]
18. The Role of Ribosomal Protein S6 Kinases in Plant Homeostasis.
Obomighie I; Lapenas K; Murphy BE; Bowles AMC; Bechtold U; Prischi F
Front Mol Biosci; 2021; 8():636560. PubMed ID: 33778006
[TBL] [Abstract][Full Text] [Related]
19. S6 kinase 2 is bound to chromatin-nuclear matrix cellular fractions and is able to phosphorylate histone H3 at threonine 45 in vitro and in vivo.
Ismail HM; Hurd PJ; Khalil MI; Kouzarides T; Bannister A; Gout I
J Cell Biochem; 2014 Jun; 115(6):1048-62. PubMed ID: 23564320
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1.
Phin S; Kupferwasser D; Lam J; Lee-Fruman KK
Biochem J; 2003 Jul; 373(Pt 2):583-91. PubMed ID: 12713446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
